NASDAQ: HBIO · Industrial Applications and Services · 3 alerts · CIK 1123494
Share price
$8.91Close, Nov 16
Market cap
$40.7M
Shares outstanding
4.57MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Harvard Bioscience Inc filings on SEC EDGAR ↗
Harvard Bioscience reported revenues of $22.2 million for Q3 2026, a slight increase from $20.6 million in the prior year, though the company recorded a net loss of $2.6 million. For the nine months ended September 30, 2026, the net loss was $9.0 million compared to a $53.9 million loss in 2025, which had been driven by a significant $48.0 million goodwill impairment charge.
Harvard Bioscience filed its updated corporate slide presentation for November 2026 to provide the investment community with updates and summaries of its business operations. The presentation includes forward-looking information regarding expected financial performance, including adjusted EBITDA margins and the introduction of new products aimed at accelerating drug development.
Harvard Bioscience reported Q3 2026 revenue of $22.2 million, an 8% increase year-over-year, driven by strong demand from CROs and customers in China. The company reported a net loss of $2.6 million for the quarter and reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%.
Term
Q3 2026
“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products.”